Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Review article: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-12-21 , DOI: 10.1111/apt.16741
Jie Wang _{1,

2} , Idan Goren _{2,

3,

4} , Bo Yang ₁ , Sinan Lin _{2,

5} , Jiannan Li ₂ , Michael Elias ₂ , Claudio Fiocchi _{2,

6} , Florian Rieder _{2,

6}

Affiliation

Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis. Additional S1PR modulators are being tested in clinical development programmes for both ulcerative colitis and Crohn's disease.

中文翻译：

评论文章：1 磷酸鞘氨醇/1 磷酸鞘氨醇受体轴 - 炎症性肠病的独特治疗靶点

Ozanimod 是一种高选择性 1 磷酸鞘氨醇 (S1P) 受体 (S1PR) 1/5 调节剂，已被美国食品和药物管理局批准用于治疗患有中度至重度活动性溃疡性结肠炎的成年患者。其他 S1PR 调节剂正在溃疡性结肠炎和克罗恩病的临床开发项目中进行测试。

更新日期：2022-01-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>